Methanobrevibacter smithii in irritable bowel syndrome: a clinical and molecular study


Cite item

Full Text

Abstract

Aim. To assess the role of Methanobrevibacter smithii in patients with irritable bowel syndrome associated with small intestinal bowel overgrowth. Materials and methods. Sixty - seven patients with IBS according to Rome IV were enrolled into the study in whom hydrogen breath test was performed. Thirty - two healthy subjects with negative breath test was used as a control. All IBS symptoms assessed daily with 5 grade Lykert scale for 7 days, stool was assessed by Brystol stool scale. M. smithii was confirmed in stool samples by PCR. Results and discussion. In 67 IBS patients CH4 overproduction was found in 32 (47.7%), H2 overproduction in 31 (46.2%) and normal values in 4 (5.9%) by hydrogen breath test. M. smithii was confirmed by stool PCR in all patients with CH4 overproduction. Severity and prevalence of main clinical features of IBS were similar in both SIBO groups but were significantly higher than in control (p<0.01). Positive correlation between overproduction of CH4, abdominal pain and uncomplete bowel emptying (p<0.05). Conclusion. SIBO CH4 was found in nearly half of all patients with IBS associated with SIBO, symptoms profile and severity are similar in patients with SIBO CH4 and SIBO H2, however, the abdominal pain and uncomplete bowel emptying are associated with the level of CH4 overproduction.

About the authors

A V Vlasova

Federal Research Centre of Nutrition, Biotechnology and Food Safety

Email: alinliliya@gmail.com
врач отд-ния гастроэнтерологии и гепатологии ФГБУН «ФИЦ питания и биотехнологии»; ORCID: 0000-0003-2966-1171 Moscow, Russia

V A Isakov

Federal Research Centre of Nutrition, Biotechnology and Food Safety

д.м.н., проф., зав. отд-нием гастроэнтерологии и гепатологии ФГБУН «ФИЦ питания и биотехнологии»; ORCID: 0000-0002-4417-8076 Moscow, Russia

V I Pilipenko

Federal Research Centre of Nutrition, Biotechnology and Food Safety

н.с. отд-ния гастроэнтерологии и гепатологии ФГБУН «ФИЦ питания и биотехнологии»; ORCID: 0000-0001-5632-1880 Moscow, Russia

S A Sheveleva

Federal Research Centre of Nutrition, Biotechnology and Food Safety

д.м.н., руководитель лаб. биобезопасности и анализа нутримикробиома ФГБУН «ФИЦ питания и биотехнологии»; ORCID: 0000-0001-5647-9709 Moscow, Russia

Yu M Markova

Federal Research Centre of Nutrition, Biotechnology and Food Safety

н.с. лаб. биобезопасности и анализа нутримикробиома ФГБУН «ФИЦ питания и биотехнологии»; ORCID: 0000-0001-7767-4204 Moscow, Russia

A S Polyanina

Federal Research Centre of Nutrition, Biotechnology and Food Safety

лаборант-исследователь лаб. биобезопасности и анализа нутримикробиома ФГБУН «ФИЦ питания и биотехнологии»; ORCID: 0000-0002-2766-7716 Moscow, Russia

I V Maev

Yevdokimov Moscow State University of Medicine and Dentistry

академик РАН, д.м.н., проф., руководитель каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»; ORCID: 0000-0001-6114-564Х Moscow, Russia

References

  1. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. doi: 10.2147/CLEP.S40245
  2. Gwee K.A, Wee S, Wong M.L, Png D.J. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am J Gastroenterol. 2004;99:924-31. doi: 10.1111/j.1572-0241.2004.04161.x
  3. Thompson W.G, Longstreth G.L, Drossman D.A, Heaton K, Irvine E.L, Muller-Lissner S. Functional bowel disorders and functional abdominal pain. In: Drossman D.A, ed. The functional gastrointestinal disorders. 2nd ed. McLean, VA: Degnon Associates, 2000. P. 351-432.
  4. Healton Kenneth W, Tompson W. Grant Fast Facts - Irritable Bowel Syndrome. Oxford: Health Print Ltd, 1999.
  5. Stockbrugger R, Pace F. The irritable bowel syndrome manual. London; Milan; Philadelphia; Hong Kong: Mosby - Wolfe Medical Communications, 1999.
  6. Thompson W. Grant. The road to Rome. Gastroenterology. 2006;130:1552-6.
  7. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real - time PCR. Am J Gastroenterol. 2005;100(2):373-82. doi: 10.1111/j.1572-0241.2005.40312.x
  8. King T.S, Elia M, Hunter J.O. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187-9.
  9. Pimentel M, Lin H.C. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1089-G1095. doi: 10.1152/ajpgi.00574.2004
  10. Nucera G, Gabrielli A, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21:1391-5. doi: 10.1111/j.1365-2036.2005.02493.x
  11. Spiegel B.M.R. Questioning the Bacterial Overgrowth Hypothesis of Irritable Bowel Syndrome: An Epidemiologic and Evolutionary Perspective. Clin Gastroenterol Hepatol. 2011;9:461-9. doi: 10.1016/j.cgh.2011.02.030
  12. Quigley E.M.M, Stanton C, Murphy E.F. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol. 2013;58:1020-7. doi: 10.1016/j.jhep.2012.11.023
  13. Miller T.L, Wolin M.J. Methanogens in human and animal intestinal tracts. System Appl Microbiol. 1986;7:223-9.
  14. Stefano M.D, Corazza G.R. Role of hydrogen and methane breath testing in gastrointestinal diseases. Digest Liv Dis. 2009;3(Suppl 2):40-3. doi: 10.1016/S1594-5804(09)60018-8
  15. Fernandes J, Wolever T, Rao A.V. Interrelationships between age, total dietary fiber intake and breath methane in humans. Nutrit Res. 2000;20:929-40. doi: 10.1016/S0271-5317(00)00184-6
  16. Johnston C, Ufnar J.A, Griffith J.F, Gooch J.A, Stewart J.R. A real - time qPCR assay for the detection of the nifH gene of Methanobrevibacter smithii, a potential indicator of sewage pollution. J Appl Microbiol. 2010;109(6):1946-56. doi: 10.1111/j.1365-2672.2010.04824.x
  17. Samuel B.S, Hansen E.E, Manchester J.K, et al. Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut. Proc Natl Acad Sci. 2007;104(25):10643-8. doi: 10.1073/pnas.0704189104
  18. Ивашкин В.Т., Зольникова О.Ю. Синдром раздраженного кишечника с позиций изменений микробиоты. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):84-92. doi: 10.22416/1382-4376-2019-29-1-84-92
  19. Levitt M.D, Furne J.K, Kuskowski M, et al. Stability of human methanogenic flora over 35 years and review of insights obtained from breath methane measurements. Clin Gasrtoenterol Hepatol. 2006;4:123-9. doi: 10.1016/j.cgh.2005.11.006
  20. Gottlieb K, Wacher V, Sliman J, et al. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther. 2016;43(2):197-212. doi: 10.1111/apt.13469
  21. Пилипенко В.И., Исаков В.А., Балмашнова А.В. Пищевые паттерны больных с синдромом избыточного бактериального роста в кишечнике. Вопросы диетологии. 2018;8(1):17-26. doi: 10.20953/2224-5448-2018-1-17-26

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies